Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf164 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Xiao Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: Glycolysis, Lymphoma, Extranodal NK-T-Cell. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program, Chang Jiang Scholars Program.
Abstract (Originalsprache)
Background
The post-treatment Deauville scale (DS) and circulating Epstein-Barr virus (EBV)-DNA were used for prediction of long-term remission in natural killer/T-cell lymphoma (NKTCL). However, the baseline biomarkers still remain lacking for clinical application. Here, we hypothesized that 18F-FDG PET/CT, as a measure of total tumor burden, would be a baseline biomarker to identify high-risk NKTCL patients.
Methods
We analyzed PET/CT data in early-stage NKTCL patients (n = 192) receiving pegaspargase-based regimens from 2 independent clinical trials. The prognostic values of radiomic markers including total lesion glycolysis (TLG), standardized uptake value, and metabolic tumor volume were evaluated in the training (n = 127) and validation cohorts (n = 65) with a median follow-up of 37 months.
Results
Total lesion glycolysis was a prognosticator of progression-free survival (PFS) and overall survival (OS), with 86.11% and 91.30% sensitivity and 55.77% and 53.25% specificity, respectively, which outperformed the risk model based on posttreatment DS and circulating EBV-DNA (sensitivity 53.85% and specificity 54.24% for PFS, sensitivity 43.75% and specificity 52.34% for OS). Five-year PFS and OS were 92.19% and 96.82% in the low TLG group (<75 g), versus 69.46% and 77.24% in the high TLG group (≥75 g). ScRNA-seq (n = 10) and bulk RNA-seq (n = 65) data from patients in the trials both revealed that inflammatory dendritic cells, as immunosuppressive signature, were significantly infiltrated in patients with high TLG compared with patients with low TLG.
Conclusions
Baseline TLG reflected an immunosuppressive microenvironment and was an effective radiomic marker for long-term remission in patients with early-stage NKTCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine…
- Department of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai 200025, China.
ORCID-Profile: Jie Xiong
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program
- Chang Jiang Scholars Program
- Shanghai Rising-Star Program
- Shanghai Municipal Commission of Science and Technology Project
- Shanghai Clinical Research Center for Cell Therapy
- Clinical Research Plan of Shanghai Hospital Development Center
Zitieren
APA
Gao, X., Xiong, J., Huang, X. Y., Yang, H. X., Zhong, H. J., Cheng, S., Jiang, X. F., & Zhao, W. L. (2025). Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma. The Oncologist. https://doi.org/10.1093/oncolo/oyaf164
Vancouver
Gao X, Xiong J, Huang XY, Yang HX, Zhong HJ, Cheng S, et al. Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma. The Oncologist. 2025. doi:10.1093/oncolo/oyaf164
BibTeX
@article{Gao2025,
author = {Gao, Xiao and Xiong, Jie and Huang, Xin-Yun and Yang, Hao-Xu and Zhong, Hui-Juan and Cheng, Shu and Jiang, Xu-Feng and Zhao, Wei-Li},
title = {Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf164}
}
EUVIMED